Abstract: The present invention is directed to an osmotic engine useful in an osmotic delivery system for delivery of a beneficial agent in a controlled manner over a preselected administration period. By including a flowable engine comprising at least one osmotic agent and at least one fluid vehicle, the resulting osmotic engine reaches a zero order push power or push rate quickly and provides steady delivery of the beneficial agent.

Abstract: The present invention is directed to an osmotic engine useful in an osmotic delivery system for delivery of a beneficial agent in a controlled manner over a preselected administration period. By including a flowable engine comprising at least one osmotic agent and at least one fluid vehicle, the resulting osmotic engine reaches a zero order push power or push rate quickly and provides steady delivery of the beneficial agent.

Abstract: An article of apparel is disclosed that includes an electronic device. The apparel is at least partially formed from a material element that defines an aperture. The electronic device is locatable within the aperture and removably-securable to the material element. The electronic device may be a timing device, such as a watch, or a global positioning system unit. The apparel may be a wristband formed from a textile material or any of a variety of other types of apparel.

Abstract: The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Abstract: The present invention includes devices and methods for reducing the start-up time of osmotically driven drug delivery systems capable of delivering a desired drug at a controlled rate over time. In particular, the present invention includes osmotic pumps that have a preloaded membrane, which includes a semipermeable material that has been preloaded with a nonaqueous, incompressible liquid filler that is miscible with water. The present invention further includes methods for making such osmotic pumps. The preloaded membranes included in the osmotic pumps according to the present invention have proven to provide significant decreases in average start-up times relative to osmotic pumps that include semipermeable membranes that are not preloaded.

Abstract: The present invention includes materials and methods for providing vehicles useful for providing drug formulations that address the potential drawbacks of known nonaqueous formulations. In particular, the present invention includes nonaqueous vehicles that are formed using a combination of polymer and solvent that results in a vehicle that is miscible in water. The nonaqueous vehicles facilitate the formulation of drug formulations that are stable over time, even when stored at, or exposed to, elevated temperatures. Moreover, the miscible vehicles of the present invention allow the preparation of drug formulations that work to reduce the occurrence of partial or complete occlusions of the delivery conduits included in delivery devices used to administer the drug formulations.

Abstract: The present invention provides a suspension vehicle and suspension formulations deliverable from an implantable delivery device. In particular, the suspension vehicle of the present invention allows the formulation of beneficial agent suspensions that are stable over time at ambient and physiological temperatures. In addition, the beneficial agent suspensions formed using the suspension vehicle of the present invention allow controlled delivery of beneficial agent from an implanted delivery device over sustained periods of time, even when such delivery occurs at low-flow rates, through a small-diameter delivery channel. Also included in the present invention are implantable delivery devices.

Abstract: The present invention is directed to an osmotic engine useful in an osmotic delivery system for delivery of a beneficial agent in a controlled manner over a pre preselected administration period. By including a flowable engine comprising at least one osmotic agent and at least one fluid vehicle, the resulting osmotic engine reaches zero a zero order push power or push rate quickly and provides steady delivery of the beneficial agent.

Abstract: This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1×10−7 reciprocal second.

Abstract: A microwave filter cavity that exhibits spurious mode suppression. The microwave filter comprises a metal mode suppression tuning stub located in a replaceable iris plate that is used to suppress unwanted transverse magnetic (TM) modes of the filter cavity, The mode suppression stub is disposed normal to an end wall of the cavity. The mode suppression stub perturbs the E-field of transverse magnetic modes, while having negligible effect on desired transverse electric (TE) modes. The addition of the tuning stub has no effect on filter performance determined by transverse electric modes.

Abstract: In a filter assembly having a bandpass filter and a group-delay equalizer coupled thereto by a circulator, there is disposed in the filter and/or the equalizer an electromagnetic wave propagation structure having a cavity with a plurality of tuning elements extending therein. The wave-propagation structure supports a first wave propagating in a first mode and a second wave propagating in a second mode. A first of the tuning elements is positioned to interact with the first wave, a second of the tuning elements is positioned to interact with the second wave, and a third of the tuning elements is positioned for coupling electromagnetic energy between the first wave and the second wave. A fourth of the tuning elements has an orientation perpendicular to an orientation of the third tuning element.

Abstract: An apparatus for and method of control of a switch (102) in an electrical power converter (100) using pulse width modulation to regulate output voltage (112) and current The method allows precise output voltage regulation to be achieved whilst accurately controlling the proportion of load-current supplied by multiple modules connected in parallel. A ramped waveform (408), consisting of a component representing the instantaneous current and a component representing the input voltage applied since the switch (102) switched on in the current PWM cycle, is compared with an error signal (406) to determine the width of each PWM pulse.

Abstract: An apparatus for and method of control of a switch (102) in an electrical power converter (100) using pulse width modulation to regulate output voltage (112) and current. The method allows precise output voltage regulation to be achieved whilst accurately controlling the proportion of load-current supplied by multiple modules connected in parallel. A ramped waveform (408), consisting of a component representing the instantaneous current and a component representing the input voltage applied since the switch (102) switched on in the current PWM cycle, is compared with an error signal (406) to determine the width of each PWM pulse.

Abstract: Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.

Abstract: Mycophenolate mofetil and mycophenolic acid can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil or mycophenolic acid liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.

Abstract: The invention provides a method and apparatus for a memory device interface between a memory device and a CPU as well as the dimensions of the memory device. An electric circuit of the present invention has one-hundred-twenty pins along the length of the housing. The housing of the memory device has a length of approximately 85.6 mm and a width of approximately 54.0 mm. The left and right side socket interface portions of the housing have a minimum width of approximately 3.3 mm. The top socket interface portion has a maximum thickness of approximately 3.5 mm and a minimum height of approximately 3.0 mm. The bottom socket interface portion has a maximum thickness of approximately 5.0 mm and a minimum height of approximately 10.5 mm. Furthermore, the memory device interface portion of the present invention includes at least one pin which provides access to an address signal which indicates a memory array address location within the memory device.

Abstract: Mycophenolate mofetil, mycophenolic acid, and ranolazine can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil, mycophenolic acid, or ranolazine liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.

Abstract: Mycophenolate mofetil and mycophenolic acid can be conveniently manufactured into high dose oral formulations by the hot melt filling of a supercooled mycophenolate mofetil or mycophenolic acid liquid into a pharmaceutical dosage form. High dose oral pharmaceutical formulations and manufacturing methods therefor are disclosed.

Abstract: Acid-sensitive antibiotic esters for oral administration to livestock are stabilized by incorporation in premix formulations comprising a carrier, a base, a protective coating, and optionally a sealant film.